Sandoz, a Novartis division, has strengthened its pipeline by entering into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706) for the treatment of multiple types of cancers.
Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF), a key mediator of angiogenesis in cancer, and is used in combination with other treatments1,2.
Bio-Thera Solutions will maintain responsibility for development and manufacturing, whilst Sandoz will have the right to commercialise the medicine upon approval in the US, Europe**, Canada and selected other countries. According to the terms of the agreement, Bio-Thera Solutions will receive an upfront and milestone payments and is entitled to receive profit share payments in the partnered territory.
This agreement builds on Sandoz’s leading off-patent oncology portfolio, which comprises four marketed oncology biosimilars and over 50 generic medicines worldwide3,4. A statement from Sandoz claimed that the company is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access, while contributing to sustainability of healthcare systems.
 Avastin®, INN-bevacizumab – European Medicines Agency. Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf. [Last accessed: August 2021].
 European Medicines Agency. Summary of Product Characteristics. Available from https://www.ema.europa.eu/en/documents/overview/equidacent-epar-medicine-overview_en.pdf. [Last accessed: August 2021].
 Sandoz data on file.
 IQVIA through 2020, definition excludes biosimilars.